Keywords: Eli Lilly, Solanezumab, Alzheimer's disease, Ph III, Cognitive decline

Mixed results with Eli Lilly Alzheimer's drug solanezumab, but investors pleased

Article | 09 October 2012

Print This

US pharma major Eli Lilly (NYSE: LLY) yesterday reported detailed results from two Phase III studies for solanezumab, EXPEDITION1 and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in